Portal de Periódicos da CAPES

Pancreatic Adenocarcinoma, Version 2.2012

2012; National Comprehensive Cancer; Volume: 10; Issue: 6 Linguagem: Inglês

10.6004/jnccn.2012.0073

1540-1413

Margaret A. Tempero, J. Pablo Arnoletti, Stephen W. Behrman, Edgar Ben‐Josef, Al B. Benson, Ephraim S. Casper, Steven J. Cohen, Brian G. Czito, Joshua D.I. Ellenhorn, William G. Hawkins, Joseph M. Herman, John P. Hoffman, Andrew H. Ko, Srinadh Komanduri, Albert C. Koong, Wen Wee, Mokenge P. Malafa, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Aaron R. Sasson, Anitra Tally, Sarah P. Thayer, Samuel H. Whiting, Robert A. Wolff, Brian M. Wolpin, Deborah A. Freedman-Cass, Dorothy A. Shead,

Gastric Cancer Management and Outcomes

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.